Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Capital Expenditures (2020 - 2023)

Terns Pharmaceuticals' Capital Expenditures history spans 4 years, with the latest figure at $44000.0 for Q4 2023.

  • For Q4 2023, Capital Expenditures rose 29.41% year-over-year to $44000.0; the TTM value through Dec 2023 reached $52000.0, down 81.09%, while the annual FY2024 figure was $42000.0, 19.23% down from the prior year.
  • Capital Expenditures reached $44000.0 in Q4 2023 per TERN's latest filing, up from $8000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $430000.0 in Q1 2020 to a low of -$8000.0 in Q3 2022.
  • Average Capital Expenditures over 4 years is $89357.1, with a median of $43000.0 recorded in 2021.
  • Peak YoY movement for Capital Expenditures: surged 1380.0% in 2021, then plummeted 110.81% in 2022.
  • A 4-year view of Capital Expenditures shows it stood at $47000.0 in 2020, then skyrocketed by 325.53% to $200000.0 in 2021, then crashed by 83.0% to $34000.0 in 2022, then rose by 29.41% to $44000.0 in 2023.
  • Per Business Quant, the three most recent readings for TERN's Capital Expenditures are $44000.0 (Q4 2023), $8000.0 (Q3 2023), and $34000.0 (Q4 2022).